

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

DR. REDDY'S LABORATORIES S.A. AND
DR. REDDY'S LABORATORIES, INC.

Petitioners

v.

INDIVIOR UK LIMITED.

Patent Owner

U.S. PATENT NO. 9,687,454

TITLE: SUBLINGUAL AND BUCCAL FILM COMPOSITIONS

Case No. IPR2019-00329

PETITIONERS' UPDATED EXHIBIT LIST

Mail Stop PATENT BOARD
Patent Trial and Appeal Board
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

List of Exhibits for U.S. Patent No. 9,687,454 Petition for *Inter Partes* Review

Ex. No.	Description
1001	U.S. Patent No. 9,687,454
1002	File History of U.S. Patent Application No. 14/989,669
1003	Expert Declaration of Nandita Das, Ph.D.
1004	Curriculum Vitae of Nandita Das, Ph.D.
1005	U.S. Patent No. 8,475,832
1006	PCT Application No. WO 2008/02579 (“Euro-Celtique”)
1007	2004 Physician’s Desk Reference (“Suboxone PDR”)
1008	European Medicines Agency Initial Marketing-Authorisation Document for Suboxone® Tablet (“EMA”) (2006)
1009	Affidavit of Christopher Butler
1010	U.S. Patent Pub. No. 2011/0033541 (“Myers”)
1011	File History of U.S. Patent Application No. 12/537,571
1012	Aulton, et al., <i>Pharmaceutics The Science of Dosage Form Design</i> , Second Edition (2002) (“Aulton”)
1013	Dawson, et al., <i>pH, buffers, and physiological media</i> , Data for Biochemical Research, 428 (1986) (“Dawson”)
1014	U.S. Patent Application Publication No.: US 2005/0085440 A1 (“Birch”)
1015	Cassidy, et al., <i>Controlled buccal delivery of buprenorphine</i> , Journal of Controlled Release, 21-29 Volume 25 (1993) (“Cassidy”)
1016	Campbell, et al., <i>The history of the development of buprenorphine as an addiction therapeutic</i> , Ann. N.Y. Acad. Sci. 124–139 (2012) (“Campbell”)

1017	Chiang, et al., <i>Pharmacokinetics of the combination tablet of buprenorphine and naloxone</i> , Drug and Alcohol Dependence S39 - S47 Volume 70 (2003) (“Chiang”)
1018	Bullingham, et al., <i>Sublingual Buprenorphine Used Postoperatively: Clinical Observations and Preliminary Pharmacokinetic Analysis</i> , British Journal of Clinical Pharmacology, 117-122 Volume 12 (1981) (“Bullingham”)
1019	European Patent Application No. 82303582.9 (“Todd”)
1020	U.S. Patent No. 5,288,497 (“Stanley”)
1021	<i>Suboxone</i> , European Medicines Agency, https://www.ema.europa.eu/medicines/human/EPAR/suboxone (Last visited Oct. 26, 2018) (“EMA Web”)
1022	Ciraulo, et al., <i>Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials</i> , The Journal of Clinical Pharmacology, 179-192 Volume 46 (2006) (“Ciraulo”)
1023	<i>Reckitt Benckiser Pharma, Inc. v. Watson Labs., Inc.</i> , 13-cv-1674-RGA (D. Del. June 26, 2015)
1024	Suboxone® Tablet Label (2002)
1025	Batheja, P. et al., Basic Biopharmaceutics of Buccal and Sublingual Absorption <i>in</i> Enhancement in Drug Delivery (Elke Touitou and Brian W. Barry, eds., 2007) (“Batheja”)
1026	Corrected Declaration of Robert Frederickson III in Support of Petitioners’ Renewed Motion for <i>Pro Hac Vice</i> Admission
1027	Declaration of Anjum Swaroop
1028	Transcript of June 28, 2018 Hearing of Motion for a Preliminary Injunction
1029	Declaration of Alexandra D. Valenti In Support of Petitioners’ Motion for <i>Pro Hac Vice</i> Admission

CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. §§ 42.6(e) and 42.105(a), the undersigned certifies that on November 12, 2019, a copy of the foregoing **Updated Exhibit List** was served electronically via e-mail on the following:

dgarr@cov.com

pchen@cov.com

IndiviorSBX@cov.com

Date: November 12, 2019

By: /Ira J. Levy/
Registration No. 35,587
Goodwin Procter LLP
The New York Times Building
620 Eighth Avenue
New York, NY 10018-1405
T: 212-459-7459
F: 646-558-4143
ILevy@goodwinlaw.com